The reaction of skin to primers used in the "single-step" bonding systems

A large number of direct bonding systems have been introduced for use by dentists and dental hygienists. Although these agents are used for direct bonding of brackets to enamel, contact with skin, oral mucosa, and gingiva is not uncommon. These products have wide clinical use, but their biocompatibility characteristics have not been extensively investigated. The present study was undertaken to determine the effects of the primer component of Mono-Lok (Rocky Mountain) and the primer component of Control (Lancer Pacific) on skin. Three adult Macaca mulatta monkeys were used in the study. The skin on their backs was shaved and the primer component of Control, primer component of Mono-Lok, and saline solution were applied at different sites every 3 days for up to four applications. The skin was examined clinically and, 5 days after the last application, a biopsy was performed for histologic evaluation. The skin in contact with the primer component of Mono-Lok exhibited pronounced inflammatory changes and was characterized by swelling, vesiculation, and ulceration. Histologic observations confirmed these findings by showing a marked inflammatory cellular response characterized by eosinophils. In contrast to these findings, the skin in contact with the primer component of Control or saline solution exhibited normal architecture. Histologic observations supported this appearance and showed minimal inflammatory cell infiltration. These results show that there are differences in the biocompatibility of direct bonding systems and that further studies are needed to clarify their long-term effects on patients and dental personnel.     

CEA and CA 19.9: an evaluation by new statistical technics on a group of elderly patients

New parametric and non parametric statistical methods have been compared in the evaluation of experimental data of CEA and CA 19.9 using a brief program in BASIC. We have found that the distribution of the two markers is the same of that described in literature except for both the means that we have found being slightly higher than that ones described by other authors.     

Acute hemodynamic effects of piroximone (MDL 19,205) in patients with moderate congestive heart failure: comparison with sodium nitroprusside

Piroximone (MDL 19,205), a new imidazolone derivative, was given intravenously to 14 patients with congestive heart failure (NYHA class II-III), while under constant daily doses of digitalis and diuretics. In the first 3 patients, we determined the dose safely eliciting a favorable hemodynamic response. The subsequent 11 patients received 1 mg/kg of piroximone intravenously, and the hemodynamic effects were compared with those of sodium nitroprusside (SN) at a dose-lowering mean blood pressure by 10-20 mm Hg. Piroximone increased heart rate (13.2 +/- 2.0 beats/min, mean +/- SEM) and lowered mean arterial pressure (9 +/- 2.3 mm Hg). Both agents reduced similarly wedge pressure (6.5 +/- 2.9 and 9 +/- 2.9 mm Hg, respectively, for SN and piroximone) and total peripheral resistance. Cardiac index was increased less by SN (15%) than piroximone (48%) (p less than 0.001), and stroke work index significantly enhanced only by piroximone (p less than 0.001). The changes in loading conditions induced by the two agents being similar, it is likely that piroximone not only acts by peripheral vasodilation, but also possesses positive inotropic properties. Myocardial oxygen demand, assessed indirectly by tension-time index, was not affected by piroximone. Thus, piroximone appears to combine well-balanced vasodilator and inotropic properties which make this new agent potentially very useful for the management of congestive heart failure.